PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fosamprenavir→

Fosamprenavir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
226700-79-4
PubChem CID
131536
Molecular formula
C25H36N3O9PS
Molecular weight
585.6 g/mol
Drug class
HIV-1 protease inhibitor prodrugantiretroviral agent
Mechanism of action
Fosamprenavir is a phosphate prodrug that is hydrolysed to amprenavir. Amprenavir inhibits HIV-1 protease, preventing cleavage of viral gag-pol polyproteins and production of mature infectious virions.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and eligible paediatric patients; current use depends on resistance profile, drug interactions and national treatment guidelines

Sources: US DailyMed — LEXIVA (fosamprenavir) · NLM MeSH — Fosamprenavir · FDA product information

Identification source: PubChem record (CID 131536). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fosamprenavir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fosamprenavir Permitted Daily Exposure (PDE) report (the Fosamprenavir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fosamprenavir Occupational Exposure Limit (OEL) report (the Fosamprenavir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.